Getty Images
A woman died in Virginia after applying Johnson & Johnson’s COVID vaccine: Another is in critical condition
An alarm was raised in the United States on Tuesday, after the CDC (Centers for Disease Control and Prevention) and the FDA (U.S. Food and Drug Administration) revealed that of the nearly 7 million doses have put on Johnson & Johnson’s COVID vaccine, 6 people reported suffering a worrying side effect: the appearance of blood clots. That is why they asked to temporarily suspend the application of this drug, until they thoroughly investigate the cases.
Most troubling of all is that of the six people who after receiving the dose of J&J had serious adverse effects, one of them, a woman from the state of Virginia died.
Another, from the state of Nebraska, is in critical condition in a hospital, the New York Times revealed.
The media quoted added that both the dead woman who got the Johnson & Johnson vaccine and the one who is hospitalized, as well as the other four remaining, were all female patients, between the ages of 18 and 48.
FOX News revealed that health authorities are investigating the death of the woman, whose identity was not revealed, as part of the wider investigation they launched to learn more about the “adverse side effects” of the woman. Johnson & Johnson vaccine reported so far,
FOX cited Virginia state vaccination coordinator Danny Avula, who confirmed that the woman’s death in question occurred last March and is being investigated to determine whether or not there were effects related to the vaccination. Johnson & Johnson vaccine that may have triggered his death.
The official warned that when the woman’s death occurred, she was reported to the CDC’s Vaccine Adverse Event Notification System.
“We are closely monitoring federal government actions to stop all Johnson & Johnson vaccines while investigating a possible extremely rare side effect. In Virginia, we will stop all Johnson & Johnson vaccines until this investigation is completed,” he said. official, in his statement.
“This pause is reassuring, as it shows that the systems that exist to monitor vaccine safety are working. We expect a thorough review by federal health officials. In the meantime, we will continue to launch the Virginia vaccine this year. moment with the other two authorized vaccines, developed by Pfizer and Moderna, “he added. “People who have received the Johnson & Johnson vaccine and who develop severe headache, abdominal pain, leg pain, or difficulty breathing within three weeks of vaccination should contact their care provider. or call 911 if it is a medical emergency. “
On the woman who is in serious condition in the state of Nebraska, the local television newscaster 6 News said she was a 48-year-old woman “vaccinated with Johnson & Johnson Lot No. 1,805,020 on March 9.” .
On her condition, the media said: “She is currently hospitalized with deep bleeding and clotting, suspected dysfibrinogenemia …. The CDC report, through the Adverse Event Notification System for vaccines known as VAERS, lists the condition of the woman as serious and “potentially fatal.”
After announcing the situation with the Johnson & Johnson vaccine, Dr. Peter Marks, director of the FDA’s Center for Biological Assessment and Research and Dr. Anne Schuchat, senior deputy director of the CDC said in a statement:
“People who have received the J&J vaccine and who develop severe headache, abdominal pain, leg pain, or difficulty breathing within three weeks of vaccination should contact their care provider. medical ”.
“Healthcare providers are asked to report adverse events to the Vaccine Adverse Event Notification System at https://vaers.hhs.gov/reportevent.html,” they added.
Officials added: “At this time, these adverse events appear to be extremely rare. The safety of the COVID-19 vaccine is a top priority for the federal government, and we take very seriously all reports of health problems after the COVID-19 “vaccination.
The FDA and the @CDCgov issued a statement on the Johnson & Johnson vaccine for the # COVID-19[FEMININE. Recomanem una pausa en l’ús d’aquesta vacuna per precaució. https://t.co/EOaNEScaRL
– US FDA en Espanyol (@FDAenEspanol) 13 d’abril de 2021
Sobre les troballes en els sis casos reportats van esmentar: “En aquests casos, es va observar un tipus de coàgul de sang anomenat trombosi de si venós cerebral (CVST) en combinació amb nivells baixos de plaquetes en sang (trombocitopènia). Els sis casos van ocórrer entre dones d’entre 18 i 48 anys, i els símptomes es van presentar de 6 a 13 dies després de la vacunació. El tractament d’aquest tipus específic de coàgul sanguini és diferent de el tractament que normalment s’administra. En general, s’usa un medicament anticoagulant anomenat heparina per tractar els coàguls de sang. En aquest context, l’administració d’heparina pot ser perillosa i cal administrar tractaments alternatius “.
Segueix a Ara mateix a Instagram
